Development of Store-Operated Calcium Entry-Targeted Compounds in Cancer

Xiaojing Liang; Ningxia Zhang; Hongming Pan; Jiansheng Xie; Weidong Han

doi:10.3389/fphar.2021.688244

Development of Store-Operated Calcium Entry-Targeted Compounds in Cancer

Front Pharmacol. 2021 May 28:12:688244. doi: 10.3389/fphar.2021.688244. eCollection 2021.

Authors

Xiaojing Liang¹, Ningxia Zhang¹, Hongming Pan¹, Jiansheng Xie^{1

2}, Weidong Han¹

Affiliations

¹ Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
² Laboratory of Cancer Biology, Institute of Clinical Science, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Abstract

Store-operated Ca²⁺ entry (SOCE) is the major pathway of Ca²⁺ entry in mammalian cells, and regulates a variety of cellular functions including proliferation, motility, apoptosis, and death. Accumulating evidence has indicated that augmented SOCE is related to the generation and development of cancer, including tumor formation, proliferation, angiogenesis, metastasis, and antitumor immunity. Therefore, the development of compounds targeting SOCE has been proposed as a potential and effective strategy for use in cancer therapy. In this review, we summarize the current research on SOCE inhibitors and blockers, discuss their effects and possible mechanisms of action in cancer therapy, and induce a new perspective on the treatment of cancer.

Keywords: SOCE; cancer; inhibitor; pharmacodynamics; therapy.

Publication types

Review